

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/568,745
				Filing Date	02-21-06
				First Named Inventor	Mitsuko Ideno
				Art Unit	1644
				Examiner Name	Z. SKELDING
(Use as many sheets as necessary)				Attorney Docket Number	
Sheet	1	of	8	1422-0709PUS1	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initial *	Cite No.	Foreign Patent Document Country ³ Number ⁴ Kind Code (if known) ⁵	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	Where Relevant Passages or Relevant Figures Appear
5	WO	00/09168-A1	02-24-2000			
6	WO	01/62895-A2	08-30-2001			
7	WO	03/08017 - A1	02-10-2003			
8	EP	0409655-A2	01-23-1991			
9	EP	1424387 - A1	06-02-2004			
10	EP	1666589 - A1	06-07-2006			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation design number (optional). 2 See Kind Codes of USPTO patent documents at MPEP 901.04. 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.14. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time it takes you to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

If you need assistance in completing the form, call 1-800-PTO-0100 (1-800-766-0100) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 8

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/568,745
				Filing Date	02-21-06
				First Named Inventor	Mitsuko Ideno
				Art Unit	1644
				Examiner Name	Z. SKELDING
(Use as many sheets as necessary)				Attorney Docket Number	
Sheet	2	of	8	1422-0709PUS1	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initial *	Cite No.	Foreign Patent Document Country ³ Number ⁴ Kind Code (if known) ⁵	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
11	JP	2003-80817 - A	03-19-2003			
12	WO	2004-018667 - A1	03-04-2004			
13	WO	2005/019450 - A1	03-03-2005			
14	JP	3-284700-A	12-16-1991			
15	JP	3-80076-A	04-04-1991			
16	JP	5-271291-A	10-19-1993			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER, Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include copy of this form next communication to applicant. 1. Applicant's unique citation design number (optional). 2) See Kits Codes of USPTO patent documents, at www.uspto.gov or MPEP 901.04. 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

If you need assistance in completing the form, call 1-800-PTO-8160 (1-800-773-8160) and select option 2.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1669A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 8

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/568,745
				Filing Date	02-21-06
				First Named Inventor	Mitsuko Ideno
				Art Unit	1644
				Examiner Name	Z. SKELDING
(Use as many sheets as necessary)				Attorney Docket Number	
Sheet	3	of	8	1422-0709PUS1	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initial *	Cite No. 1	Foreign Patent Document Country ³ Number ⁴ Kind Code (if known) ⁵	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	Where Relevant
17	WO	97/01194-A1	01-09-1997			
18	WO	97/11694-A1	04-03-1997			
19	WO	99/33663-A1	07-08-1999			

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation design number (optional). 2 See Kits Codes of USPTO patent documents, at www.uspto.gov or MPEP 901.04. 3. The reissue Office that issued the document, by the two-letter code (WIPO Standard ST) 4. For Japanese patent documents, at the issuance of the year the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form for the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this inquiry and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 8

Complete if Known

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Art Unit	1644
Examiner Name	Z. SKELDING

Attorney Docket Number 1422-0709PUS1

NON PATENT LITERATURE DOCUMENTS

Examiner initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	20	"Animal Cell Culture: A Practical Approach", Edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C., 1986, pp. 26-41	<input type="checkbox"/>
	21	ANIMAL CELL CULTURE METHODS, edited by R. Freshney, Moscow, "Mir", 1989, pages 44, 53, 77 (the original English "Animal Cell Culture - A Practical Approach"), edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C.	<input type="checkbox"/>
	22	BENIGNI, Fabio et al.; Phenotype and Homing of CD4 Tumor-Specific T Cells is Modulated by Tumor Bulk; <i>The Journal of Immunology</i> ; 2005, 175, pp. 739-748.	<input type="checkbox"/>
	23	DARDALHON et al., "Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector." <i>Blood</i> , Vol. 96, No. 3, 2000, pp. 885-893.	<input type="checkbox"/>
	24	FUNARO et al., "Stimulation of T Cells via CD44 Requires Leukocyte-Function-Associated Antigen Interactions and Interleukin-2 Production", <i>Human Immunology</i> , Vol. 40, 1994, pps. 267-278	<input type="checkbox"/>
	25	GATTINONI et al., "Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells," <i>J. Clin. Invest.</i> , Vol. 115, No. 6, 2005, pp. 1616-1626.	<input type="checkbox"/>
	26	HALVORSON et al., "alpha4 and alpha5 integrins costimulate the CD3-dependent proliferation of fetal thymocytes," <i>Cell. Immunol.</i> , Vol. 189, No. 1, 1998, pp. 1-9.	<input type="checkbox"/>
	27	HIBINO et al., "Tenascin Suppresses CD3-Mediated T Cell Activation", <i>Biochemical and Biophysical Research Communications</i> , Vol. 250, 1998, pp. 119-124.	<input type="checkbox"/>
	28	IDENO et al., "RetroNectin® Kumiaiawaseta T Saibo Kakudai Baiyo (II): Kakudai Baiyo sareta T Saibo Shudan wa NaiveT-ye Saibo no Hiritsu ga Takaku, Takai Kogen Nishikino o Hakki," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330.	<input type="checkbox"/>
	29	IDENO et al., "Soshikitai Human Fibronectin Fragment Shigeki ni you Kasseika CTL no Tairyō Expansion-ho," Dai 62 Kai Annual Meeting of the Japan Cancer Association Kiji, 2003, pp. 175.	<input type="checkbox"/>

Examiner Signature

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to applicant.

1. Applicant's unique citation designation number, (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

8

		<i>Complete if Known</i>	
		Application Number	10/568,745
		Filing Date	02-21-06
		First Named Inventor	Mitsuko Ideno
		Art Unit	1644
		Examiner Name	Z. SKELDING
		Attorney Docket Number	1422-0709PUS1

NON PATENT LITERATURE DOCUMENTS

Examiner initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	30	International Search Report in International Application No. PCT/JP02/08298 mailed December 3, 2002	<input type="checkbox"/>
	31	JPO International Search Report, Appl. No. PCT/JP2006/315881, October 10, 2006	<input type="checkbox"/>
	32	JPO International Search Report, Appl. No. PCT/JP2006/319105, January 9, 2007	<input type="checkbox"/>
	33	Kim YOUNG-JUNE et al., "4-1BB Costimulation Promotes Human T Cell Adhesion to Fibronectin", Cellular Immunology 192, 13-23 (1999)	<input type="checkbox"/>
	34	KOBERDA et al., "Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., Vol. 119, 1993, pp. 131-136.	<input type="checkbox"/>
	35	MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 1133-1148.	<input type="checkbox"/>
	36	MIKAMO, "Bulk Culture of Human Lymphocytes", Cell Technology, 1995, 14:2, 223-227.	<input type="checkbox"/>
	37	MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988.	<input type="checkbox"/>
	38	MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT- yo Saibo ga Kohintsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330.	<input type="checkbox"/>
	39	Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English translation.	<input type="checkbox"/>

Examiner Signature

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique case identification number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

8

		<i>Complete if Known</i>
		Application Number
		Filing Date
		First Named Inventor
		Art Unit
		Examiner Name
		Z. SKELDING
		Attorney Docket Number
		1422-0709PUS1

NON PATENT LITERATURE DOCUMENTS

Examiner initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	40	Office Action in Chinese Application No. 200480024172.7 mailed November 30, 2007, including English translation.	<input type="checkbox"/>
	41	RAO, W. H. et al, "Potent Costimulation of Effector T Lymphocytes by Human Collagen Type I," J Immunol. 2000, vol. 165, pp. 4935-4940	<input type="checkbox"/>
	42	Retronectin, 2010, Takara Bio. Inc., http://catalog.takara-bio.co.jp/en/PDFFiles/T100A_B_e.pdf.p.1-8	<input type="checkbox"/>
	43	SAGAWA et al., "Ko-CD3 Kotai to RetroNectin??o Kumiawaseru Koto ni yoru LAK Saibo Inyu Ryoho no Kairoyo," Dai 62 Kai Annual Meeting of the Japan Cancer Association Kiji, 2003, pp. 438.	<input type="checkbox"/>
	44	SEKINE, "Expansion of Lymphocytes by Culture with Immobilized Anti-CD3 Monoclonal Antibody and Interleukin-2 for Use in Adoptive Immunotherapy of Cancer Patients", Saibo Baiyo (Cell Culture), Vol. 17, No. 6, 1991, pp. 192-195.	<input type="checkbox"/>
	45	SHUQIN et al., "Induction of Allogenic Cytotoxic T Lymphocytes and Their Culture", Journal of South China Normal University (Natural Science Edition), No. 4, 1994, pp. 11-17 (including partial English language translation)	<input type="checkbox"/>
	46	SIMON, Markus M. et al., The outer surface lipoprotein A of Borrelia burgdorferi provides direct and indirect augmenting/co-stimulatory signals for the activation of CD4+ and CD8+ T cells", Immunol. Lett., 1995, Vol. 46, No. 3, pp. 137-142.	<input type="checkbox"/>
	47	STOHL et al., "Generation of Cytolytic Activity with Anti-CD3 Monoclonal Antibodies Involves Both IL-2-Independent and -Dependent Components", J. Immunol., Vol. 144, No. 10, May 15, 1990, pp. 3718-3725	<input type="checkbox"/>
	48	STURM, A., et al, "Dual Function of the Extracellular Matrix: Stimulatory for Cell Cycle Progression of Naive T Cells and Antia apoptotic for Tissue-Derived Memory T Cells," The Journal of Immunology, 2004, vol. 173, pp. 3889-3900	<input type="checkbox"/>
	49	Supplementary European Search Report issued by the EPO in corresponding European Application No. 06782667.7 on September 16, 2009.	<input type="checkbox"/>

Examiner Signature

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include cite of this form with next communication to applicant.

1. Applicants unique citation designation number, (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

8

Complete if Known

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Art Unit	1644
Examiner Name	Z. SKELDING

Attorney Docket Number 1422-0709PUS1

NON PATENT LITERATURE DOCUMENTS

Examiner initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <input type="checkbox"/>
	50	TAKAYAMA et al., "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial", <i>The Lancet</i> , Vol. 356, 2000, pp. 802-807	<input type="checkbox"/>
	51	US Office Action for Application No. 10/344,534, dated November 6, 2009	<input type="checkbox"/>
	52	US Office Action for Application No. 10/344,534, mailed May 13, 2008	<input type="checkbox"/>
	53	US Office Action for Application No. 10/344,534, November 24, 2009	<input type="checkbox"/>
	54	US Office Action for Application No. 10/486,512, dated June 25, 2004	<input type="checkbox"/>
	55	US Office Action for Application No. 10/509,055, dated May 11, 2007	<input type="checkbox"/>
	56	US Office Action for Application No. 10/509,055, mailed February 10, 2011	<input type="checkbox"/>
	57	US Office Action, dated August 31, 2010, for US Application No. 11/990,443	<input type="checkbox"/>
	58	US Office Action, dated December 28, 2010, for US Application No. 11/992,661	<input type="checkbox"/>
	59	US Office Action, dated February 10, 2011, for US Application No. 10/509,055	<input type="checkbox"/>

Examiner Signature

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered; include copy of the form or next communication by applicant.

1. Applicants under citation number 1 through 2. Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is promised in 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
 SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

8

of

8

		<i>Complete if Known</i>
		Application Number
		Filing Date
		Mitsuko Ideno
		Art Unit
		Z. SKELDING
		Attorney Docket Number
		1422-0709PUS1

NON PATENT LITERATURE DOCUMENTS

Examiner initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	60	US Office Action, dated July 6, 2011, for US Application No. 10/509,055	<input type="checkbox"/>
	61	US Office Action, dated June 9, 2011, for US Application No. 11/992,661	<input type="checkbox"/>
	62	US Office Action, dated March 16, 2011, for US Application No. 11/990,443	<input type="checkbox"/>
	63	US Office Action, dated October 14, 2010, for US Application No. 11/992,661	<input type="checkbox"/>
	64	WHITESIDE et al., "Isolation of Human NK Cells and Generation of LAK Activity, Current Protocols in Immunology", 1996, Supp. 17, Unit 7.7, pages 7.7.1-7.7.11.	<input type="checkbox"/>
	65	WILLIAMS et al., "Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions," Letters to Nature, Vol. 352, 1991, pp. 438-441	<input type="checkbox"/>
	66	WILLS, M. R., et al, "Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response," The Journal of Immunology, 2002, vol. 168, pp. 5455-5464	<input type="checkbox"/>
	67	ZHOU et al., "Molecular Mechanisms Underlying Differential Contribution of CD28 Versus Non-CD28 Costimulatory Molecules to IL-2 Promoter Activation," The Journal of Immunology, Vol. 168, 2002, pp. 3847-3854	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number, (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.